Category
104 articles — page 2 of 9
May 14, 2026
Vitiligo changes slowly — slowly enough that without consistent documentation you cannot tell whether treatment is working. Here is a practical system for tracking patches, understanding clinical scoring tools, and setting realistic timelines.
May 14, 2026
Vitiligo spreads at widely different rates — from imperceptibly slow to rapid progression over weeks. Understanding what drives spread, what rapid progression looks like, and when to act can help you respond appropriately rather than with unnecessary panic or false reassurance.
May 14, 2026
Yes — vitiligo is an autoimmune disease. Understanding what that means at a mechanistic level explains why it co-occurs with other autoimmune conditions, why JAK inhibitors work, and what treatment is actually targeting.
May 14, 2026
Vitiligo is not a painful condition in the conventional sense — but depigmented skin does create situations where pain can occur. Here is the clear answer and the specific circumstances where discomfort arises.
May 14, 2026
Vitiligo that begins after the age of 40 has a distinct profile — different triggers, different comorbidity associations, and a different prognosis trajectory compared to early-onset disease. Here is what the evidence shows.
May 14, 2026
Leukotrichia — white hair within vitiligo patches — is more than a cosmetic feature. It indicates deeper follicular melanocyte loss and significantly affects repigmentation prognosis. Here is what it means and why it matters.
May 14, 2026
Surgical melanocyte transplantation is the most effective option for stable vitiligo that has not responded to medical treatment — particularly in areas with depleted follicular reserves. Here is how it works, who qualifies, and what outcomes look like.
May 14, 2026
Minocycline is a tetracycline antibiotic used off-label for vitiligo because of its anti-inflammatory and immunomodulatory properties — not its antibiotic effect. The evidence is limited but the rationale is plausible. Here is the honest picture.
May 14, 2026
Narrowband UVB and excimer laser both emit 308nm therapeutic UV but deliver it very differently. Choosing between them depends on how much of your body is affected, your access to equipment, and your budget. Here is the head-to-head comparison.
May 14, 2026
The three main topical approaches to vitiligo — JAK inhibitor (Opzelura), calcineurin inhibitor (tacrolimus), and corticosteroids — each have different mechanisms, evidence levels, side effects, and appropriate uses. Here is the complete comparison.
May 14, 2026
Polypodium leucotomos is an oral fern extract with antioxidant and photoprotective properties. The evidence base for its use as a phototherapy adjunct in vitiligo is modest but real — here is what the trials actually show.
May 14, 2026
Pseudocatalase cream (PC-KUS) is frequently asked about in vitiligo communities. The evidence is weak, the mechanism is contested, and the product is not widely available. Here is the honest assessment.
